Search clinical trials for: Prevention of Meningococcal Meningitis

Total 428308 results

Aimei Vacin BioPharm (Zhejiang) Co., Ltd.

Not yet recruiting

A Study of the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine

Meningococcal Meningitis

China
CanSino Biologics Inc.

Recruiting

Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)

Epidemic Meningitis

China
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Active, not recruiting

Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 Months

Meningitis, Meningococcal

China
CanSino Biologics Inc.

Active, not recruiting

A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a 4 to 6 Year-old Population

Epidemic Meningitis

China
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Completed

Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 35 Months

Meningitis, Meningococcal

China
Wei Cun
Yunnan Center for Disease Control and Prevention

Unknown

A Phase III Clinical Trial of the Group A Meningococcal Polysaccharide Vaccine

Meningitis, Meningococcal

China
Wei Cun
Yunnan Center for Disease Control and Prevention

Unknown

A Phase III Clinical Trial of the Group A and C Meningococcal Polysaccharide Vaccine

Meningitis, Meningococcal

China
Walvax Biotechnology Co., Ltd.

Completed

Safety Evaluation of Meningococcal Group ACYW135 Conjugate Vaccine in 2-month to 55 Years Old Population.

Meningococcal Infections

China
Epicentre
Medecins Sans Frontieres, Netherlands

Withdrawn

Ciprofloxacin for the Prevention of Meningococcal Meningitis 2018

Meningitis, Meningococcal

Niger
Merck Sharp & Dohme LLC

Completed

RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)

Meningitis, Meningococcal | Rotavirus Infections
Epicentre
Medecins Sans Frontieres, Netherlands

Completed

Ciprofloxacin for the Prevention of Meningococcal Meningitis

Meningitis, Meningococcal

Niger
Novartis Vaccines
GlaxoSmithKline

Completed

Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

Serogroup B Meningococcal Meningitis

Austria, Czechia, Finland, Germany, Italy
Novartis Vaccines
GlaxoSmithKline

Completed

Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12

Meningococcal Disease | Meningococcal Meningitis

Belgium, Czechia, Germany, Italy, Spain, United Kingdom
Novartis Vaccines
GlaxoSmithKline

Completed

Persistence of Antibody Response to N. Meningitidis Group C in Children

Prevention of Meningococcal Infection

Spain, Poland
Novartis
Novartis Vaccines

Completed

Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers

Meningococcal Disease | Meningococcal Meningitis

Poland
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Air Force Military Medical University, China; Guizhou Center for Disease Control... and other collaborators

Unknown

Immunogenicity and Safety of Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of Age

Meningitis | Meningococcal Infections | Meningococcal Meningitis

China
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Air Force Military Medical University, China; Guangxi Center for Disease Control... and other collaborators

Unknown

Safety Study of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months

Meningitis, Meningococcal

China
Novartis Vaccines

Completed

Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children

Meningococcal Infections

Canada, United States
Beijing Minhai Biotechnology Co., Ltd

Completed

Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine

Meningitis

China
Beijing Minhai Biotechnology Co., Ltd

Completed

Immunogenicity and Safety of Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine

Meningitis

China
University of British Columbia
Canadian Institutes of Health Research (CIHR)

Completed

Evaluation of Meningococcal C Vaccine Programmes in Canadian Children

Meningococcal Sero-type C Infection

Canada
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years

Meningococcal Disease | Meningococcal Meningitis

Australia, Canada
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines

Meningococcal Disease | Meningococcal Meningitis

Chile, Colombia, Panama
Novartis Vaccines

Completed

Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine

Prevention of Meningococcal Infection

United Kingdom
Novartis
Novartis Vaccines

Completed

Kinetics of B Cell Response in Infants Menjugate Vaccination

Prevention of Meningococcal Infection

United Kingdom
Novartis
Novartis Vaccines

Completed

Persistence of Immune Response After Vaccination With MCC

Prevention of Meningococcal Infection

United Kingdom
Jiangsu Province Centers for Disease Control and...
Royal (Wuxi) Biological Co., LTD

Completed

Phase 3 Study of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine

Influenza | Meningitis

China
Novartis Vaccines

Completed

Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers

Meningococcal Infections

United States
Jiangsu Province Centers for Disease Control and...
Royal (Wuxi) Biological Co., LTD

Completed

Immunogenicity and Safety of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Infants and Children

Group A, C Polysaccharide Meningitis | Type b Haemophilus Influenza

China
Novartis Vaccines

Completed

Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children

Prevention of Meningococcal Infection

Germany, Poland
Centers for Disease Control and Prevention
Johns Hopkins University; University of Pittsburgh; Maryland Department of Health... and other collaborators

Completed

Effect of Meningococcal Conjugate Vaccine on Meningococcal Carriage

Meningitis
Novartis
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age

Prevention of Meningococcal Infection

Italy
Epicentre
University of Oslo; Norwegian Institute of Public Health; Medecins Sans Frontieres...

Completed

Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine

Infections, Meningococcal | Meningitis, Meningococcic

Norway, Uganda
CanSino Biologics Inc.

Not yet recruiting

Clinical Study of the Safety of Menhycia® in 3-Month-Old Infants

Epidemic Meningitis
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Recruiting

Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli)

Healthy Volunteers

China
CanSino Biologics Inc.

Not yet recruiting

A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds

Meningococcal Meningitis
CanSino Biologics Inc.

Not yet recruiting

A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years

Meningococcal Meningitis

Indonesia
GlaxoSmithKline

Not yet recruiting

A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age

Meningitis, Meningococcal

Korea, Republic of
University of Rochester
Fogarty International Center of the National Institute of Health; Infectious... and other collaborators

Recruiting

Meningitis: Burden, Causes, Screening and Prevention in Rural Northern Uganda

Meningitis

Uganda
Xuanwu Hospital, Beijing

Not yet recruiting

Establishment of Prevention and Control System of Central Nervous System Infection

Encephalitis | Meningitis | Central Nervous System (CNS) Infection

China
Centre Hospitalier Intercommunal Creteil
Association Clinique Thérapeutique Infantile du val de Marne

Recruiting

Long-term Sequelae of Childhood Meningitis and Meningococcal Purpura Fulminans (SEINE)

Meningitis, Meningococcal | Sequela

France
Center for Vaccine Development - Mali
University College, London; University of Oxford; Public Health England; University... and other collaborators

Recruiting

A Human Controlled Infection Study With Neisseria Lactamica in Malian Adults

Meningitis, Meningococcal

Mali
National Institute of Allergy and Infectious Diseases...

Recruiting

Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection

Gonococcal Infection

United States, Thailand, Malawi
Emory University
National Institute of Allergy and Infectious Diseases (NIAID)

Active, not recruiting

Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate Vaccine

Meningitis

Mali
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Active, not recruiting

Immunogenicity and Safety of MCV4 in Volunteers Aged 6 Months-5 Years

Healthy Population

China
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Active, not recruiting

Immunogenicity and Safety of Group A and C Meningococcal Polysaccharide Conjugate Vaccine in Volunteers Aged 3-5 Months

Healthy Population

China
GlaxoSmithKline

Active, not recruiting

Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age

Infections, Meningococcal

United States, Italy
GlaxoSmithKline

Completed

Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults

Infections, Meningococcal

United States, Australia, Finland, Estonia, Canada, Turkey, Czechia
GlaxoSmithKline

Active, not recruiting

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

Infections, Meningococcal

United States, Puerto Rico
Pfizer

Completed

Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ≥10 Years of Age

Meningococcal Vaccine

Poland, Czechia, Turkey

Search clinical trials for: Prevention of Meningococcal Meningitis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations